hero image

Biogen Idec Announces March 25 Webcast of Research & Development Day

March 18, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) announced today that it will hold its 2009 R&D Day on Wednesday, March 25, 2009 from 1 PM ET to 5 PM ET. Dr. Cecil Pickett, Biogen Idec's President of Research & Development, along with members of the Company's R&D leadership team will provide a detailed review of the Company's pipeline programs.

Media, investors and the general public can access the live event by visiting the "Investor" section of the Biogen Idec web site, investor.biogenidec.com. Audio and slide presentations will be available through the web site. An archived version of the webcast will be available for 30 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

 

Contact:

Biogen Idec
Investor Relations
Rob Jacobson, 617-679-2812

thumb
April 24, 2024
BIOGEN TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS APRIL 24, 2024

Cambridge, Mass.— Biogen Inc . (Nasdaq:BIIB) today announced it will report first quarter 2024 financial results Wednesday, April 24, 2024, before the financial markets open. Following the release of the financials, the Company will host a live webcast with Biogen management at 8:30 a.m. ET.

thumb
March 31, 2024
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

TOKYO and CAMBRIDGE, Mass., April 1, 2024 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai submitted to the U.S.